Both Casgevy and Lyfgenia are highlighted in a recent Clarivate report among 13 potential “blockbuster and gamechanger” drugs to watch in 2024. Vertex's gene-editing therapy for sickle cell ...

President Trump signed an executive order on the day of his inauguration that created doubts about the future of a program to ...

On the same day the FDA signed off on Casgevy in sickle cell disease, the agency also approved bluebird bio’s cell-based gene therapy Lyfgenia (lovotibeglogene autotemcel). The company already ...

The two new therapies—Vertex Pharmaceuticals’ Casgevy and BlueBird Bio’s Lyfgenia—offer the 100,000 Americans and nearly 8 million people globally who suffer from sickle cell potential ...

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

Opinions expressed by Forbes Contributors are their own. Joshua Cohen is a Boston-based writer who covers health policy. The Biden Administration announced this week that the manufacturers of ...

Discover the latest addition to Children's Hospital Los Angeles' 10 cell and gene therapy treatments, including Casgevy for sickle cell disease ...

Casgevy, a once-and-done treatment for sickle ... Bluebird bio's gene therapies Zynteglo and Lyfgenia were recently approved to treat beta-thalassemia and sickle cell disease, respectively.

Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with ...

Vertex Pharmaceuticals (VRTX) announced a reimbursement agreement with NHS England for eligible sickle cell disease patients to access the ...

HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its gene-editing therapy for sickle cell disease.